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Summary
It has been shown in animal models that matrix metalloproteinases (MMPs) and their inhi-
bitors (TIMPs) are responsible for remodelling and neovascularization of the diseased cornea. 
Under normal conditions, MMPs are expressed at relatively low levels, which may increase in 
case of different corneal diseases. In this paper we have investigated gene expression of matrix 
metalloproteinase 2, matrix metalloproteinase 13 and their inhibitor TIMP-1, in keratoconus, bu-
llous keratopathy and vascularized corneal scar; aiming to determine whether these molecules 
are differentially expressed in epithelium of diseased human corneas. Keratoconus, bullous ke-
ratopathy and vascularized corneal scar were chosen for two reasons: they represent low-, inter-
mediate- and high-risk corneal disease regarding corneal graft rejection rate (respectively) and 
they are very common reason for corneal transplantation. Our results have show that in bullous 
keratopathy, expression of both MMP-13 and MMP-2 genes were significantly increased compa-
red to vascularized corneal scar and keratoconus; however only MMP-13 reached significance 
in our relatively small human sample. These results are comparable to our previously published 
data on protein levels of MMPs in diseased human corneal epithelium, where we showed signi-
ficant increase of MMP-13 and MMP-2 proteins in patients with bullous keratopathy compared 
to keratoconus. TIMP-1 gene expression remained constant across all groups of patients, impli-
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cating that this molecule does not play significant role in pathological epithelial changes during 
keratoconus, bullous keratopathy and vascularized corneal scar. Our results may be useful in de-
velopment of new therapeutic agents both to treat pathological corneal changes and to prevent 
corneal graft rejection after corneal transplantation.
Keywords: cornea; matrix metalloproteinase; keratoconus; bullous keratopathy; vascularized 
corneal scar.
INTRODUCTION
Healthy cornea is avascular and transparent in order to provide good vision. 
It consists mainly of extracellular matrix (ECM) predominantly built of different 
types of collagen [1]. In case of corneal disease, highly organized corneal architectu-
re is disrupted, the extracellular matrix (ECM) is degraded, and new disorganized 
ECM is formed, resulting in the loss of corneal transparency [2].Matrix metallopro-
teinases (MMPs) are extracellular endopeptidases which have a key role in ECM 
remodelling; they are controlling intercellular interactions and interactions of cells 
with ECM [3].  More than 20 members of human MMP family has been identified 
and classified into five subgroups: gelatinases, collagenases, matrilysins, stromel-
ysins and membrane-type MMPs. Under normal conditions, MMPs are expressed 
at relatively low levels, which may increase in case of different corneal diseases. 
MMP-2, MMP-9, MMP-13 and MMP-14, for example, have been shown to participate 
in corneal wound healing and in the pathogenesis of inflammatory corneal diseases 
[4-8]. Tissue inhibitors of matrix metalloproteinase (TIMPs) are specific inhibitors of 
MMPs which regulate and control the activity of MMPs in tissues [9-12].
In the advanced stage of many corneal diseases, corneal transplantation (CT) 
is needed to restore normal corneal transparency. Based on the inflammatory pro-
file of their corneas at the time of CT patients are usually divided to be of low-risk 
(keratoconus - KC), intermediate risk (bullous keratopathy - BK) or high-risk (vas-
cularized corneal scar - VCS) for postoperative graft rejection. Keratoconus is a non-
inflammatory corneal thinning followed by anterior protrusion of the cornea, for 
which aetiology is not known and various genetic and environmental factors have 
been suggested [13,14]. Bullous keratopathy is a corneal disorder characterized by 
corneal stromal oedema with epithelial bullae formation due to endothelial cell loss 
decompensation; while vascularised corneal scar represents typical inflammatory 
corneal condition in which prolonged inflammation and neovascularisation lead to 
the loss of corneal transparency [15]. 
To aid in developing efficacious post-CT therapies for those patients, it is impor-
tant to understand and further investigate the complex pathways related to MMP 
and TIMP signalling in particular human corneal disease [16,17]. Therefore, we have 
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investigated gene expression of MMPs and TIMPs in the corneal epithelium of pati-
ents suffering from KC, BK and VCS at the time of CT. Although it has been shown 
in animal model that those molecules promote pathological cellular interactions le-
ading to remodelling and neovascularization of corneal tissue, it is still not known 
whether they are differentially expressed in high-, intermediate and low-risk hu-
man corneal diseases [18,19].
MATERIALS AND METHODS
Tissue preparation
With the proper informed consent and approval by the Ethical Committee of 
our Hospital human corneal epithelium was taken ex vivo from 18 recipient corneal 
buttons obtained during corneal transplantation (7 diagnosed with keratoconus, 6 
with bullous keratopathy and 5 with vascularized corneal scar). Corneal epithelium 
was separated from the corneal stroma by fine forceps under the operating micros-
cope, and homogenized using the TissueRuptor homogenizer (Qiagen, Germany). 
Control healthy epithelium (n=5) was collected from healthy corneas obtained from 
the eye bank.
RNA isolation
Total human corneal epithelial RNA was extracted from the individual corneal 
epithelium using Rneasy Mini Kit (Qiagen, Hilden, Germany); cDNA was prepared 
from 1 µg of purified total RNA in 20 µl reaction volume, using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA), according 
to manufacturer's instructions. Real-time PCR analysis was carried out on an ABI 
7300 sequence detection system (Applied Biosystems, Foster City, CA) to quantify 
relative mRNA expression of matrix metallopeptidase 2 (MMP-2), matrix metallo-
peptidase 13 (MMP-13) and tissue inhibitor of MP-1 (TIMP-1) genes, respectively. 
Assay IDs used for the analysis are shown in Table 1. The housekeeping gene gapdh 
was used as an endogenous control to normalize the total amount of cDNA in each 
sample. Reactions were carried out in a total volume of 20 μl using TaqMan® Gene 
Expression Master Mix reagent (Applied Biosystems, Foster City, CY, USA) and 5 μl 
of cDNA for template with forward and reverse primers. Using the 2-∆∆Ct method, 
data are presented as the fold-change in gene expression normalized to an endo-
genous reference gene and relative to the control. All reactions were carried out in 
triplicate [20].
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Table 1. Primers used for quantitative real-time PCR analysis








Statistical analyses of data were performed using R v2.15.3 (CRAN, http://cran.r-
project.org) and RStudio for Windows, v0.97 (http://www.rstudio.com/). For the 
analysis of real-time PCR data, all groups were tested for normality of distribution 
using Shapiro-Wilk test. The differences between multiple groups were compared 
with Kruskall-Wallis non-parametric ANOVA, followed by Wilcoxon signed-rank 
test for testing differences between two related groups. For all tests significance 
level was set at p < 0.05. 
RESULTS
MMP-2 gene expression in corneal epithelium of patients with keratoconus, 
bullous keratopathy and vascularised corneal scar
The expression of MMP-2 gene remained unchanged in patients with keratoco-
nus, bullous keratopathy and vascularised corneal scar when compared to control 
patients, as revealed by Kruskal-Wallis non-parametric ANOVA (Kruskal-Wallis 
chi-squared = 6.8404, df = 3, p-value = 0.07716) (Fig. 1). 
MMP-13 gene expression in  corneal epithelium of patients with keratoconus, 
bullous keratopathy and vascularised corneal scar
The MMP-13 gene expression was not determined in patients with keratoconus 
because the expression of the MMP-13 gene was below detection limit of the met-
hod. Kruskal-Wallis non-parametric ANOVA has shown significant differences in 
MMP-13 gene expression between BK and VCS groups (Kruskal-Wallis chi-squared 
= 6, df = 2, p-value = 0.049). In patients with bullous keratopathy MMP-13 gene was 
significantly upregulated, as revealed by Wilcoxon rank-sum test (W=8, p = 0.012) 
(Fig. 2). 
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TIMP-1 gene expression in corneal epithelium of patients with keratoconus, 
bullous keratopathy and vascularised corneal scar
TIMP1 gene expression remained unchanged in any of groups, when compared to 







































Figure 1. Real-time PCR analysis of MMP-2 gene expression in corneal epithelium of patients 
with keratoconus, bullous keratopathy and vascularised corneal scar. Fold-change in gene 
expression compared to control was calculated using the 2–ΔΔCT method as described in Materials 
and methods. Data are presented as fold-change ±SE on log scale. 
Figure 2. Real-time PCR analysis of MMP-13 gene expression in corneal epithelium of patients 
with keratoconus, bullous keratopathy and vascularised corneal scar. Fold-change in gene 
expression compared to control was calculated using the 2–ΔΔCT method as described in Materials 
and methods. Data are presented as fold-change ±SE on log scale. 
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DISCUSSION
Corneal transplantation (CT) is one of the most frequently performed transplan-
tations [21]. However, the molecular mechanisms leading to corneal opacification in 
different corneal diseases are still not well determined. From the clinical experience 
we know that the outcome of CT significantly varies according to the characteristi-
cs of the recipient cornea where the corneal graft is placed. Therefore, it is of great 
importance to understand which molecules are involved in pathological changes of 
corneal tissue in different diseases; both to invent new topical agents to treat those 
diseases and to improve the surgical prognosis of CT. Based on the experimental 
data in animal models it is clear that MMPs play an important role in changes of 
ECM and thus transparency of the cornea, and that their activity is regulated via 
TIMPs [8-12,22,23]. However, very little data on MMPs and TIMP role in changes of 
corneal transparency are available for human corneas [24-27]. For this reason we 
were interested whether any changes in gene expression of MMPs and TIMPs could 
be detected in human low-risk disease like keratoconus (KC) versus intermediate 
and high-risk ones like bullous keratopathy (BK) and vascularized corneal scars 
(VCS). In the study of Gordon et al., an comprehensive analysis for the entire MMP 
gene expression during mouse corneal abrasion injury was done, and it has been 
shown that mRNA levels for several MMPs and TIMP-1 were significantly upre-



































Figure 3. Real-time PCR analysis of TIMP-1 gene expression in corneal epithelium of patients 
with keratoconus, bullous keratopathy and vascularised corneal scar. Fold-change in gene 
expression compared to control was calculated using the 2–ΔΔCT method as described in Materials 
and methods. Data are presented as fold-change ±SE on log scale. 
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epithelialization suggesting that MMP-13 may be a marker of prolonged corneal 
epithelial injury [12]. In our study, we have shown that MMP-13 gene is significantly 
upregulated also in human epithelium of patients with BK, but not in KC and VCS, 
suggesting specific role of MMP-13 in epithelial corneal changes in patients with 
BK. In our previously published paper, we have also investigated protein levels of 
different MMPs and TIMPs in BK and KC corneas, and have similarly shown that 
epithelium of BK patients show higher level of MMP-13 protein compared to KC 
[27].  Moreover, we have shown that protein levels of epithelial TIMP-1 remained 
unchanged in both KC and BK [27]. This finding is also confirmed by gene expressi-
on analysis in this study, where no difference was found in TIMP-1 gene expression 
between BK, KC and VSC corneas. Although MMP-2 gene analysis in this study 
showed higher gene expression in the epithelium of BK and VCS patients compared 
to KC, this difference was not statistically significant. However, our previous prote-
in analysis of MMP-2 showed increased MMP-2 levels in patients with BK compared 
to KC [27]. Current results may have been influenced by the relatively small sample 
in this study, so further investigations would be beneficial for confident conclusion 
whether MMP-2 has a role in corneal epithelial changes in BK patients. Overall, one 
may conclude that MMP-13 plays a role in pathological changes of corneal epithe-
lium in BK, since both MMP-13 gene and protein are highly expressed in corneal 
epithelium of such patients. 
CONCLUSION
Presented results revealed that the expression of MMP-13 gene is significantly 
increased in bullous keratopathy (BK), somewhat increased in vascularized corneal 
scar (VCS) and under levels of detection in keratoconus (KC). Although MMP-2 gene 
expression was increased in patients with BK and VCS compared to keratoconus, 
this difference did not reach significance in this relatively small sample. TIMP-1 
gene expression remained constant across all groups of patients. 
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Sažetak
Genska ekspresija matriks metaloproteinaze 2, matriks metaloproteinaze 13 te tkivnog 
inhibitora matriks metaloproteinaze 1 u epitelu oboljelih ljudskih rožnica
Matriks metaloproteinaze (MMP) i njihovi inhibitori (TIMP) smatraju se čimbenicima od-
govornim za remodelaciju i neovaskularizaciju rožnice do koje dolazi kod raznih bolesti, što je 
pokazano na životinjskim modelima. U zdravim rožnicama matriks metaloproteinaze izražene 
su u relativno niskim koncentracijama te rastu u slučaju rožničnih bolesti. U ovome smo radu 
istražili gensku ekspresiju matriks metaloproteinaze 2 i 13 u ljudskim bolestima rožnice keratoko-
nusu, buloznoj keratopatiji i vaskulariziranim ožiljcima rožnice kako bismo stekli uvid u to imaju 
li ti MMP-ovi značenje u razvitku humanih bolesti rožnice. Keratokonus, bulozna keratopatija 
i vaskularizirani ožiljci odabrani su iz dva razloga: zbog toga što klinički predstavljaju bolesti 
niskog, intermedijarnog i visokog rizika glede ishoda transplantacije rožnice te zbog toga što su 
to učestale indikacije zbog kojih se obavlja transplantacija rožnice. Naši rezultati pokazuju da u 
slučaju bulozne keratopatije dolazi do povišene ekspresije i MMP-13 i MMP-2 gena u usporedbi 
s keratokonusom i vaskulariziranim ožiljcima; međutim samo je povišena ekspresija MMP-13 bila 
signifikantna u našoj relativno maloj skupini bolesnika. Ti rezultati podudaraju se s našim pret-
hodnim istraživanjima u kojima smo proteinskom analizom dokazali da su i MMP-13 i MMP-2 
protein signifikantno više producirani u epitelu rožnica bolesnika s buloznom keratopatijom nego 
u onih s keratokonusom. Razina ekspresije TIMP-1 gena nije se razlikovala među ispitivanim 
uzorcima ukazujući na to da ta molekula nema bitnu ulogu u patološkim promjenama epitela u 
slučaju keratokonusa, bulozne keratopatije i vaskulariziranih ožiljaka. Dobiveni rezultati mogli 
bi biti korisni u razvitku novih terapija kako za liječenje patoloških rožničnih promjena, tako i za 
liječenje reakcije odbacivanja transplantata rožnice.
Ključne riječi: rožnica; matriks metaloproteinaze; keratokonus; bulozna keratopatija; vasku-
larizirani ožiljci rožnice.
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